Back to Cell Types

NCI-H1781Homo sapiens (Human)Cancer cell line

Also known as: NCIH1781, H-1781, H1781, NSI-H1781

🤖 AI SummaryBased on 9 publications

Quick Overview

Human lung cancer cell line with known RB mutations and potential for drug sensitivity studies.

Detailed Summary

The NCI-H1781 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is characterized by the presence of RB gene mutations, which are common in SCLC and play a critical role in cell cycle regulation and tumor suppression. This cell line has been used in studies investigating the molecular mechanisms of SCLC, including the role of RB in tumor progression and the identification of potential therapeutic targets. Research on NCI-H1781 has contributed to understanding the genetic and proteomic profiles of SCLC, highlighting the importance of RB in the pathogenesis of this cancer type. The cell line is also valuable for studying the effects of targeted therapies and drug sensitivity in SCLC models.

Research Applications

Molecular mechanisms of SCLCRB gene mutation analysisDrug sensitivity studiesProteomic profilingTherapeutic target identification

Key Characteristics

RB gene mutationsSmall Cell Lung Cancer originPotential for drug response studiesProteomic and genomic profiling

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1494
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	66
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Minimally invasive lung adenocarcinoma
Lineage	Lung
Subtype	Lung Adenocarcinoma
OncoTree Code	LUAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000379_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Val157Phe (c.469G>T)	Homozygous	-	Unknown
MutationSimple	PTEN	p.Gln245fs*6 (c.735_739delGCCGT)	Heterozygous	-	from parent cell line NCI-H1781

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10

D13S317

14

D16S539

8

D18S51

14

D19S433

14,16

D21S11

28,31

D2S1338

20,25

D3S1358

15

D5S818

10

D7S820

9,10

D8S1179

14

FGA

22,23

Penta D

11,13

Penta E

17

TH01

9

TPOX

10,11

vWA

14

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources